In patients with severely elevated triglyceride levels at risk for developing acute pancreatitis, the investigational drug plozasiran reduced triglyceride levels by an average of 74% after 24 weeks of use without causing any significant safety concerns, according to research presented at the American College of Cardiology's Annual Scientific Session.
Study explored the association between dietary insulin index (DII) and dietary insulin load (DIL) with metabolic healthy (MH) status and the serum levels of brain-derived neurotrophic factor (BDNF) and adropin among the Iranian adult population.
Older patients with higher triglyceride levels, mostly within the normal to high range, had lower risk of dementia and slower cognitive decline over time than those with lower triglyceride levels.
Atrial fibrillation will now be included as a common side effect in the Summary of Product Characteristics for medicinal products containing omega-3-acid ethyl esters.
1. In this randomized controlled trial, treatment with pegozafermin improved fibrosis in patients with nonalcoholic steatohepatitis (NASH). 2. Treatment with pegozafermin led to increased rates of NASH resolution. Evidence Rating Level: 1 (Excellent) Study Rundown: NASH is a disease characterized by hepatic inflammation and excess fat accumulation with or without fibrosis of the liver. Pegozafermin